84359-50-2

Basic information

• Product Name: N,N-DIPHENYLPIPERIDIN-4-AMINE
• Synonyms: N,N-DIPHENYLPIPERIDIN-4-AMINE
• CAS NO: 84359-50-2
• Molecular Formula: C₁₇H₂₀N₂
• Molecular Weight: 0
• Mol File: 84359-50-2.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,N-DIPHENYLPIPERIDIN-4-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-DIPHENYLPIPERIDIN-4-AMINE(84359-50-2)
• EPA Substance Registry System: N,N-DIPHENYLPIPERIDIN-4-AMINE(84359-50-2)

Safety Data

• Hazardous Substances Data: 84359-50-2(Hazardous Substances Data)

Upstream product

• 108-86-1 bromobenzene 
• 62-53-3 aniline 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 125541-22-2 1-(tert-butoxycarbonyl)-4-phenylaminopiperidine 
• 470689-98-6 4-diphenylaminopiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 1416053-66-1 (2R)-1-[4-(diphenylamino)piperidin-1-yl]-3-(quinolin-5-yloxy)propan-2-ol 
• 1610999-33-1 3-[4-(diphenylamino)piperidin-1-yl]-N-(3-methoxyphenyl)-N-methylpropanamide 
• 470689-99-7 4-diphenylamino-4'-methyl-[1,4']bipiperidinyl-1'-carboxylic acid tert-butyl ester 
• 470689-97-5 (4'-methyl-[1,4']bipiperidinyl-4-yl)diphenylamine 

Relevant articles and documents

HETEROCYCLICALKYL DERIVATIVE COMPOUNDS AS SELECTIVE HISTONE DEACETYLASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present invention relates to novel heterocyclicalkyl derivatives having histone deacetylase (HDAC) inhibitory activity, optical isomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel heterocyclicalkyl derivatives. The novel heterocyclicalkyl derivatives according to the present invention are selective histone deacetylase (HDAC) inhibitors, and may be effectively used for the treatment of histone deacetylase-mediated diseases, such as cell proliferative diseases, inflammatory diseases, autosomal dominant diseases, genetic metabolic diseases, autoimmune diseases, acute/chronic neurological disease, hypertrophy, heart failure, ocular diseases, or neurodegenerative diseases.

Orally Bioavailable Competitive CCR5 Antagonists

The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compounds tested were inactive on rodent CCR5, this series includes compounds that cross-react with the cynomolgus monkey (cyno) receptor. One of these compounds, i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.